First drug for rare cancer - Updates - Alimta - Brief Article
FDA Consumer - May 1, 2004
Cancer of the mesothelium--a membrane that covers and protects most of the body's internal organs--is usually associated with a history of asbestos exposure and affects the lining of the chest. About 2,000 new cases are diagnosed each year. By the time symptoms appear, th... (Read More)
Health and environmental consequences of the World Trade Center disaster - Workgroup Report
Environmental Health Perspectives - May 1, 2004, by Philip J. Landrigan,
Paul J. Lioy,
George Thurston,
Gertrud Berkowitz,
L.C. Chen,
Steven N. Chillrud,
Stephen H. Gavett,
Panos G. Georgopoulos,
Alison S. Geyh,
Stephen Levin,
Frederica Perera,
The attack on the World Trade Center (WTC) created an acute environmental disaster of enormous magnitude. This study characterizes the environmental exposures resulting from destruction of the WTC and assesses their effects on health. Methods include ambient air sampling;... (Read More)
Asbestos and international organizations - Correspondence - Letter to the Editor
Environmental Health Perspectives - May 1, 2004, by Lorenzo Tomatis
More information is available on the harmful effects of asbestos, and more incontestable epidemiologic and experimental evidence is available on its carcinogenicity, than for any other environmental agent. The first reports of its use date back more than 2,000 years. Hero... (Read More)
Human consumption of methyleugenol and its elimination from serum - Research
Environmental Health Perspectives - May 1, 2004, by Arnold Schecter,
George W. Lucier,
Michael L. Cunningham,
Kamal M. Abdo,
Greg Blumenthal,
Andrew G. Silver,
Ron Melnick,
Christopher Portier,
Dana B. Barr,
John R. Barr,
Stephen B. Stanfill,
&
Under a mandate from the U.S. Congress, the National Toxicology Program (NTP) of the U.S. Department of Health and Human Services conducts animal bioassays for carcinogenicity of potentially toxic chemicals to which the U.S. population might be exposed. Methyleugenol, a n... (Read More)
Salmedix Completes $45 Million Series C Financing
PR Newswire - March 30, 2004
SAN DIEGO, March 30 /PRNewswire/ -- Salmedix, Inc. announced today that it has completed the sale of $45 million of its Series C Preferred Stock.
New investor HIG Ventures led the round. Other new investors, OrbiMed Advisors, Easton Hunt Capital Partners, Hunt Venture... (Read More)
Salmedix, Inc. Presents Preclinical Data on Product Candidates at the American Association for Cancer Research Annual Meeting; Salmedix Founder Dennis
PR Newswire - March 25, 2004
SAN DIEGO, March 25 /PRNewswire/ -- Salmedix, Inc. announced today that company scientists and independent researchers will be presenting data supporting the potential anti-cancer activity of each of its three clinical- stage product candidates at the 95th Annual Meeting... (Read More)
Mesothelioma Applied Research Foundation Voices Continued Praise for 'Ban Asbestos in America Act'; Senate Press Conference Today Reaffirms Broad Support
PR Newswire - March 24, 2004
WASHINGTON, March 24 /PRNewswire/ -- The Mesothelioma Applied Research Foundation (MARF), the national organization dedicated to eradicating mesothelioma as a life-ending disease, today voiced its continued support for S.1115 -- the Ban Asbestos in America Act -- Sponsor... (Read More)
Hudson Health Sciences Announces Scientific Advisory Board Members
PR Newswire - March 23, 2004
SOUTH SAN FRANCISCO, Calif., March 23 /PRNewswire/ -- Hudson Health Sciences, Inc., a biopharmaceutical company headquartered in San Francisco, California announced today that six leading oncology scientists and clinical researchers have joined its Scientific Advisory Bo... (Read More)
Puget Sound Cancer Centers Plays Significant Role in Clinical Testing Of Newly Approved Cancer Drug; FDA Approves Alimta for Treatment of Asbestos-Related
Business Wire - March 16, 2004
News Editors/Health/Medical Writers
SEATTLE--(BUSINESS WIRE)--March 16, 2004
Puget Sound Cancer Centers was actively involved in the clinical testing for the new drug Alimta, the first approved treatment for asbestos-related cancer in patients who are not candidates f... (Read More)
ADVISORY/Experts Available to Discuss Asbestos-Related Diseases
Business Wire - March 5, 2004
Business Editors
ADVISORY...
--(BUSINESS WIRE)
TOPIC: The Environmental Working Group released a report announcing 10,000 Americans die every year due to asbestos-related diseases, according to an article by Reuters. The group also expects the number of deaths to in... (Read More)
Asbestos and the pleura : a review - reviews
Chest - March 1, 2004, by David W. Cugell,
David W. Kamp
Key words: asbestos: asbestos production; DNA damage; mesothelioma; plaque: pleura; pleural calcification; pleural fibrosis; public policy; reactive nitrogen species; reactive oxygen species; rounded atelectasis; simian virus 40
Abbreviations: EPA = Environmental Protec... (Read More)
Video-assisted thoracoscopic surgery is a promising treatment for solitary fibrous tumor of the pleura - minimally invasive techniques
Chest - March 1, 2004, by Makoto Takahama,
Keiji Kushibe,
Takeshi Kawaguchi,
Michitaka Kimura,
Shigeki Taniguchi
Study objectives: Solitary fibrous tumors of the pleura (SFTPs) are slow-growing neoplasms. Approximately 800 cases have been reported in the literature to date. The aim of this study was to address our experience with the management of SFTPs and to evaluate the advantage... (Read More)
|
